The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

An Overview of the MA17R Trial in Breast Cancer

Frankie Ann Holmes, MD
Published Online: 4:19 PM, Fri July 29, 2016


Frankie Ann Holmes, MD, medical oncologist, Texas Oncology, discusses the implications of the results of the MA17R trial, which is a randomized phase III clinical trial that examined the benefits of extending aromatase inhibitors with letrozole as a treatment for postmenopausal patients with early breast cancer.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.